At 24 years old, Natasha Finch’s life took an unexpected and difficult turn when she discovered a lump in her left breast shortly after the birth of her youngest child. Initially reassured by medical professionals that the lump was likely related to hormonal changes from pregnancy, Finch faced repeated dismissal of her concerns, compounded by the perception that she was “too young for breast cancer.” It was not until spring 2020, three years after first noticing symptoms, that she was finally referred for further tests and diagnosed with invasive ductal carcinoma.

Finch, now 30 and from Wigan, described the shock of her diagnosis. Facing a stage two, grade three, triple-positive breast cancer—meaning the tumour was hormone receptor-positive and HER2-positive—she underwent intensive treatment including chemotherapy, a mastectomy, and surgery-related complications leading to sepsis. Currently on tamoxifen to reduce the risk of recurrence, Finch contends with the ongoing psychological impact of the disease, expressing persistent fear of its return.

Her case underscores growing concerns about rising breast cancer rates among younger women. While breast cancer remains most common in women over 50, recent data indicate an increase in diagnoses among those under 50, with cases rising from 6,886 in 2001 to 8,507 in 2023 in the UK. The World Cancer Research Fund also reports increases in multiple cancer types within this younger cohort, describing the trend as worrying.

Experts acknowledge breast cancer as a major public health challenge, with some high-profile cases among women in their 30s and early 40s raising awareness. However, screening guidelines currently focus on women aged 50 and over, with screening offered every three years until age 71. This leaves a gap in early detection for younger women, many of whom—like Finch—lack a family history or identifiable genetic markers that would qualify them for earlier screening.

The limitations of current assessment criteria are highlighted by a study showing that up to 95 percent of women under 50 who developed breast cancer were not classified as high risk based on family history, the primary factor considered by the National Institute for Health and Care Excellence (NICE) and the NHS. Dense breast tissue, more common in younger women, further complicates detection, as mammograms can miss tumours hidden within dense tissue.

Clinicians caution against expanding screening indiscriminately due to potential harms such as high false positive rates, unnecessary biopsies, and related anxiety. Instead, there is a call for improved strategies to identify at-risk younger women more effectively.

Finch has since become an advocate for raising awareness that breast cancer can affect young women and stresses the importance of listening to symptoms regardless of age. Her experience reflects broader challenges in balancing screening benefits and limitations, and the urgent need for revising risk assessment approaches to better serve this population.